Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 150 mg (equivalent: amylase, qty 8000 ph eur unit; equivalent: lipase, qty 10000 ph eur unit; equivalent: protease, qty 600 ph eur unit) - capsule, enteric - excipient ingredients: iron oxide yellow; sodium lauryl sulfate; macrogol 4000; iron oxide black; triethyl citrate; titanium dioxide; cetyl alcohol; dimeticone 1000; gelatin; iron oxide red; hypromellose phthalate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 300 mg - capsule, enteric - excipient ingredients: gelatin; cetyl alcohol; dimeticone 1000; iron oxide yellow; sodium lauryl sulfate; hypromellose phthalate; macrogol 4000; iron oxide red; triethyl citrate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 400 mg (equivalent: protease, qty 1600 ph eur unit; equivalent: lipase, qty 40000 ph eur unit; equivalent: amylase, qty 25000 ph eur unit) - capsule, enteric - excipient ingredients: hypromellose phthalate; iron oxide red; titanium dioxide; sodium lauryl sulfate; macrogol 4000; triethyl citrate; iron oxide black; iron oxide yellow; dimeticone 1000; gelatin; cetyl alcohol - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - dactylis glomerata, quantity: 2 ir/ml; anthoxanthum odoratum, quantity: 2 ir/ml; phleum pratense, quantity: 2 ir/ml; lolium perenne, quantity: 2 ir/ml; poa pratensis, quantity: 2 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; mannitol; aluminium hydroxide hydrate; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - lolium perenne, quantity: 2 ir/ml; phleum pratense, quantity: 2 ir/ml; poa pratensis, quantity: 2 ir/ml; anthoxanthum odoratum, quantity: 2 ir/ml; dactylis glomerata, quantity: 2 ir/ml - injection, suspension - excipient ingredients: phenol; aluminium hydroxide hydrate; water for injections; sodium chloride; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; mannitol; aluminium hydroxide hydrate; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; mannitol; phenol; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - paspalum notatum pollen (unii: v003shb7vk) (paspalum notatum pollen - unii:v003shb7vk) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - paspalum notatum pollen (unii: v003shb7vk) (paspalum notatum pollen - unii:v003shb7vk) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - paspalum notatum pollen (unii: v003shb7vk) (paspalum notatum pollen - unii:v003shb7vk) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t